Delivery Order SPE2DB20D1051-SPE2DB25FD9KH
- Not listed
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Sprycel 140mg tablets (30-count units) with a ceiling value of $11,140.74. This firm fixed-price delivery order, which carries an ultimate completion date of August 14, 2025, represents a non-competitive, non-set-aside award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Sprycel 100 mg tablets (30-count units) under a firm fixed-price contract valued at $35,010.98. The award, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-competitive delivery order executed without set-aside designation. Performance of this pharmaceutical supply contract will be fulfilled from AmerisourceBergen's Corporate Office location...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $11,013.24 on July 25, 2025, for the supply of Sprycel 100 mg tablets (30-count packages). This competitively awarded, firm fixed-price contract is non-set-aside and specifies a completion date of July 28, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $37,370.33 for Sprycel 50 mg tablets (60-count units) on September 2, 2025, with an ultimate completion date of September 3, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Sprycel 140 mg tablets (30-count units) under a firm fixed-price contract. The delivery order, valued at $5,570.37 with a completion date of July 29, 2025, represents a competitive award with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a $5,665.39 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Sprycel 100 mg tablets (30-count units) on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitive award carries no set-aside designation and is to be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical supply vendor, fulfills this order as a...
- The Defense Logistics Agency (DLA) awarded a $20,439.87 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Sprycel 100 mg tablets (30-count units) on July 30, 2025, with an ultimate completion date of July 31, 2025. This is a non-set-aside competitive award, reflecting AmerisourceBergen's demonstrated capability to meet federal pharmaceutical procurement requirements. The contract is a child delivery order under the company's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $18,016.65 delivery order to AmerisourceBergen Drug Corp on August 10, 2025, for the supply of Sprycel 80 mg tablets (quantity 30s). This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 11, 2025. This delivery order represents a routine pharmaceutical...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $18,543.22 to AmerisourceBergen Drug Corp for the supply of Sprycel 70 mg tablets (60-count units). This competitive award, issued on August 5, 2025, with an ultimate completion date of August 6, 2025, utilizes firm fixed pricing with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a $19,116.19 delivery order to AmerisourceBergen Drug Corp for 30 tablets of Sprycel 100 mg, a pharmaceutical product for oncology treatment. This delivery order, issued on September 9, 2025, represents a firm fixed-price contract with a completion date of September 10, 2025, and carries no set-aside designation. The award falls under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion...
- SPE2DB20D1051Indefinite Delivery Contract
- SPE2DB20D1051-SPE2DB25FD9KHDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Sprycel 100 mg tablets (30-count) with a ceiling value of $11,013.24 under firm fixed price terms. This non-set-aside, competitively awarded contract is classified as a delivery order and has an ultimate completion date of September 11, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This award represents a continuation of the company's established role as a critical pharmaceutical supplier to federal medical procurement needs. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This comprehensive global pharmaceutical support vehicle enables the company to supply an extensive range of medications, vaccines, and medical supplies to support military healthcare programs and other federal health systems worldwide. The underlying IDC demonstrates AmerisourceBergen's significant capacity to fulfill diverse pharmaceutical requirements across multiple therapeutic domains for the Department of Defense and its healthcare beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.0k | 9/10/25 |